A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis

Neuroscience and Biobehavioral Reviews

Volumn 65, Issue , 2016, Pages 185-194

  Davis, Justin ^a   Eyre, Harris ^a   Jacka, Felice N ^a,b,c,d   Dodd, Seetal ^a,b   Dean, Olivia ^a,b   McEwen, Sarah ^e   Debnath, Monojit ^f   McGrath, John ^g,h   Maes, Michael ^a   Amminger, Paul ^g,i   McGorry, Patrick D ^b,i   Pantelis, Christos ^b,f   Berk, Michael ^a,b,h,i  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d BLACK DOG INSTITUTE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

ⁱ THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; FOLIC ACID; HOMOCYSTEINE; IRON; MESSENGER RNA; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; SOMATOMEDIN B; VIRUS ENVELOPE PROTEIN; VITAMIN D;

AMYGDALOID NUCLEUS; ANEMIA; CANNABIS ADDICTION; COGNITIVE THERAPY; COMORBIDITY; DELUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EMOTIONAL DISORDER; EMOTIONAL STRESS; ENDOGENOUS RETROVIRUS; ENVIRONMENTAL FACTOR; EPIGENETICS; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GRAY MATTER; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROMOTION; HEREDITY; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; INTEGRATION; INTELLIGENCE QUOTIENT; INTERMETHOD COMPARISON; IRON DEFICIENCY; LOW DRUG DOSE; MEDIAL TEMPORAL LOBE; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NONHUMAN; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POVERTY; PREFRONTAL CORTEX; PREGNANCY DIABETES MELLITUS; PRENATAL CARE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN CALORIE MALNUTRITION; PROTEIN EXPRESSION; PSYCHOSIS; PSYCHOTRAUMA; RELAPSE; RETROPOSON; RETROVIRUS INFECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SEXUAL ABUSE; SMOKING; SMOKING CESSATION; SOCIAL BEHAVIOR; SOCIAL COGNITION; SOCIAL DEFEAT; SOCIAL DISABILITY; SOCIAL INTERACTION; SOCIAL STATUS; SOCIAL STRESS; SOCIAL SUPPORT; TOXOPLASMA GONDII; UNSPECIFIED SIDE EFFECT; VIRUS ACTIVATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ENVIRONMENT; GENETIC PREDISPOSITION; PHENOTYPE;

ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; RISK FACTORS; SCHIZOPHRENIA;

EID: 84962891394     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.03.017     Document Type: Review

References (132)

1. Allott K.A., Schafer M.R., Thompson A., Nelson B., Bendall S., Bartholomeusz C.F., et al. Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk participants. Schizophr. Res. 2014, 153(1-3):25-31.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Schlogelhofer M., Mossaheb N., et al. Emotion recognition in individuals at clinical high-risk for schizophrenia. Schizophr. Bull. 2012, 38(5):1030-1039.
3. Amminger G.P., Allott K., Schlogelhofer M., Thompson A., Bechdolf A., Nelson B., et al. Affect recognition and functioning in putatively prodromal individuals. Schizophr. Res. 2013, 147(2-3):404-405.
4. Antony J.M., Ellestad K.K., Hammond R., Imaizumi K., Mallet F., Warren K.G., et al. The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes. J. Immunol. 2007, 179(2):1210-1224.
5. Arias I., Sorlozano A., Villegas E., de Dios Luna J., McKenney K., Cervilla J., et al. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr. Res. 2012, 136(1-3):128-136.
6. Bediou B., Asri F., Brunelin J., Krolak-Salmon P., D'Amato T., Saoud M., et al. Emotion recognition and genetic vulnerability to schizophrenia. Br. J. Psychiatry 2007, 191:126-130.
7. Bennett M.R., Lagopoulos J. Stress and trauma: BDNF control of dendritic-spine formation and regression. Prog. Neurobiol. 2014, 112:80-99.
8. Berk M., Moylan S., Jacka F.N. A royal gift to prevention efforts. Aust. N. Z. J. Psychiatry 2014, 48(2):110-111.
9. Blackwood N.J., Howard R.J., Bentall R.P., Murray R.M. Cognitive neuropsychiatric models of persecutory delusions. Am. J. Psychiatry 2001, 158(4):527-539.
10. Blikstad V., Benachenhou F., Sperber G.O., Blomberg J. Evolution of human endogenous retroviral sequences: a conceptual account. Cell. Mol. Life Sci. 2008, 65(21):3348-3365.
11. Braehler C., Valiquette L., Holowka D., Malla A.K., Joober R., Ciampi A., et al. Childhood trauma and dissociation in first-episode psychosis, chronic schizophrenia and community controls. Psychiatry Res. 2013, 210(1):36-42.
12. Brambilla P., Perlini C., Rajagopalan P., Saharan P., Rambaldelli G., Bellani M., et al. Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study. Br. J. Psychiatry 2013, 202(1):50-55.
13. Brown A.S., McGrath J.J. The prevention of schizophrenia. Schizophr. Bull. 2011, 37(2):257-261.
14. Brudek T., Christensen T., Hansen H.J., Bobecka J., Moller-Larsen A. Simultaneous presence of endogenous retrovirus and herpes virus antigens has profound effect on cell-mediated immune responses: implications for multiple sclerosis. AIDS Res. Hum. Retroviruses 2004, 20(4):415-423.
15. Brudek T., Christensen T., Hansen H.J., Petersen T., Moller-Larsen A. Synergistic immune responses induced by endogenous retrovirus and herpesvirus antigens result in increased production of inflammatory cytokines in multiple sclerosis patients. Scand. J. Immunol. 2008, 67(3):295-303.
16. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65(1):28-37.
17. Cannon T.D. Brain biomarkers of vulnerability and progression to psychosis. Schizophr. Bull. 2015.
18. Cernis E., Vassos E., Brebion G., McKenna P.J., Murray R.M., David A.S., et al. Schizophrenia patients with high intelligence: a clinically distinct sub-type of schizophrenia?. Eur. Psychiatry 2015, 30(5):628-632.
19. Christensen T. HERVs in neuropathogenesis. J. Neuroimmune Pharmacol. 2010, 5(3):326-335.
20. Clark S.R., Schubert K.O., Baune B.T. Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. J. Neural Transm. 2015, 122(1):155-169.
21. Cohen M., Rasser P.E., Peck G., Carr V.J., Ward P.B., Thompson P.M., et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int. J. Neuropsychopharmacol. 2012, 15(3):297-307.
22. Cohen C.I., Palekar N., Barker J., Ramirez P.M. The relationship between trauma and clinical outcome variables among older adults with schizophrenia spectrum disorders. Am. J. Geriatric Psychiatry 2012, 20(5):408-415.
23. Corcoran C.M., Smith C., McLaughlin D., Auther A., Malaspina D., Cornblatt B. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr. Res. 2012, 135(1-3):170-174.
24. Couture S.M., Penn D.L., Roberts D.L. The functional significance of social cognition in schizophrenia: a review. Schizophr. Bull. 2006, 32(Suppl. 1):S44-S63.
25. Cropley V.L., Pantelis C. Using longitudinal imaging to map the 'relapse signature' of schizophrenia and other psychoses. Epidemiol. Psychiatric Sci. 2014, 23(3):219-225.
26. Cropley V., Wood S.J., Pantelis C. Brain structural, neurochemical and neuroinflammatory markers of psychosis onset and relapse: is there evidence for a psychosis relapse signature?. Int. Clin. Psychopharmacol. 2013.
27. Cullen A.E., Fisher H.L., Roberts R.E., Pariante C.M., Laurens K.R. Daily stressors and negative life events in children at elevated risk of developing schizophrenia. Br. J. Psychiatry 2014, 204:354-360.
28. Cullen A.E., Day F.L., Roberts R.E., Pariante C.M., Laurens K.R. Pituitary gland volume and psychosocial stress among children at elevated risk for schizophrenia. Psychol. Med. 2015, 45(15):3281-3292.
29. Davis J., Moylan S., Harvey B.H., Maes M., Berk M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust. N. Z. J. Psychiatry 2014.
30. Degenhardt L., Ferrari A.J., Calabria B., Hall W.D., Norman R.E., McGrath J., et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One 2013, 8(10):e76635.
31. Dickerson F., Lillehoj E., Stallings C., Wiley M., Origoni A., Vaughan C., et al. Antibodies to retroviruses in recent onset psychosis and multi-episode schizophrenia. Schizophr. Res. 2012, 138(2-3):198-205.
32. Donoghue K., Doody G.A., Murray R.M., Jones P.B., Morgan C., Dazzan P., et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014, 215(3):528-532.
33. Edwards J., Jackson H.J., Pattison P.E. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin. Psychol. Rev. 2002, 22(6):789-832.
34. Fernandes B.S., Steiner J., Berk M., Molendijk M.L., Gonzalez-Pinto A., Turck C.W., et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol. Psychiatry 2014.
35. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35(3):573-588.
36. Frank O., Jones-Brando L., Leib-Mosch C., Yolken R., Seifarth W. Altered transcriptional activity of human endogenous retroviruses in neuroepithelial cells after infection with Toxoplasma gondii. J. Infect. Dis. 2006, 194(10):1447-1449.
37. Gage S.H., Munafo M.R. Smoking as a causal risk factor for schizophrenia. Lancet Psychiatry 2015.
38. Gogtay N., Vyas N.S., Testa R., Wood S.J., Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr. Bull. 2011, 37(3):504-513.
39. Gorczynski P., Faulkner G. Exercise therapy for schizophrenia. Schizophr. Bull. 2010, 36(4):665-666.
40. Graham K.A., Keefe R.S., Lieberman J.A., Calikoglu A.S., Lansing K.M., Perkins D.O. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention Psychiatry 2014.
41. Green M.F., Bearden C.E., Cannon T.D., Fiske A.P., Hellemann G.S., Horan W.P., et al. Social cognition in schizophrenia, Part 1: performance across phase of illness. Schizophr. Bull. 2012, 38(4):854-864.
42. Green M.J., Chia T.Y., Cairns M.J., Wu J., Tooney P.A., Scott R.J., et al. Catechol-O-methyltransferase (COMT) genotype moderates the effects of childhood trauma on cognition and symptoms in schizophrenia. J. Psychiatr. Res. 2014, 49:43-50.
43. Ho B.C., Andreasen N.C., Nopoulos P., Fuller R., Arndt S., Cadoret R.J. Secondary prevention of schizophrenia: utility of standardized scholastic tests in early identification. Ann. Clin. Psychiatry 2005, 17(1):11-18.
44. Hohenadl C., Germaier H., Walchner M., Hagenhofer M., Herrmann M., Sturzl M., et al. Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation. J. Invest. Dermatol. 1999, 113(4):587-594.
45. Hooker C., Park S. Emotion processing and its relationship to social functioning in schizophrenia patients. Psychiatry Res. 2002, 112(1):41-50.
46. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66(1):13-20.
47. Howes O.D., Bose S.K., Turkheimer F., Valli I., Egerton A., Valmaggia L.R., et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. The Am. J. Psychiatry 2011, 168(12):1311-1317.
48. Hoy K., Barrett S., Shannon C., Campbell C., Watson D., Rushe T., et al. Childhood trauma and hippocampal and amygdalar volumes in first-episode psychosis. Schizophr. Bull. 2012, 38(6):1162-1169.
49. Huang W.J., Liu Z.C., Wei W., Wang G.H., Wu J.G., Zhu F. Human endogenous retroviral pol RNA and protein detected and identified in the blood of individuals with schizophrenia. Schizophr. Res. 2006, 83(2-3):193-199.
50. Jacka F.N., Berk M. Prevention of schizophrenia-will a broader prevention agenda support this aim?. Schizophr. Bull. 2014, 40(2):237-239.
51. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160(1):13-23.
52. Karama S., Ducharme S., Corley J., Chouinard-Decorte F., Starr J.M., Wardlaw J.M., et al. Cigarette smoking and thinning of the brain's cortex. Mol. Psychiatry 2015, 20(6):778-785.
53. Karlsson H., Bachmann S., Schroder J., McArthur J., Torrey E.F., Yolken R.H., Retroviral R.N.A. identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(8):4634-4639.
54. Karlsson H., Schroder J., Bachmann S., Bottmer C., Yolken R.H. HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder. Mol. Psychiatry 2004, 9(1):12-13.
55. Killackey E., Anda A.L., Gibbs M., Alvarez-Jimenez M., Thompson A., Sun P., et al. Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients. BMC Psychiatry 2011, 11:80.
56. Kirkbride J.B., Susser E., Kundakovic M., Kresovich J.K., Davey Smith G., Relton C.L. Prenatal nutrition, epigenetics and schizophrenia risk: can we test causal effects?. Epigenomics 2012, 4(3):303-315.
57. Kohler C.G., Walker J.B., Martin E.A., Healey K.M., Moberg P.J. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr. Bull. 2010, 36(5):1009-1019.
58. Koola M.M., McMahon R.P., Wehring H.J., Liu F., Mackowick K.M., Warren K.R., et al. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J. Psychiatr. Res. 2012, 46(8):987-993.
59. Krause D., Matz J., Weidinger E., Wagner J., Wildenauer A., Obermeier M., et al. The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 2010, 11(5):739-743.
60. Kumra S., Robinson P., Tambyraja R., Jensen D., Schimunek C., Houri A., et al. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51(2):171-180.
61. Laurens K.R., Cullen A.E. Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study. Soc. Psychiatry Psychiatr. Epidemiol. 2015.
62. Laurens K.R., Luo L., Matheson S.L., Carr V.J., Raudino A., Harris F., et al. Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry 2015, 15:205.
63. Leeson V.C., Barnes T.R., Hutton S.B., Ron M.A., Joyce E.M. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res. 2009, 107(1):55-60.
64. Lev-Ran S., Segev A., Braw Y., Levkovitz Y. Neurocognitive functions of heavy cannabis using schizophrenia patients. Eur. Psychiatry 2012, 27(5):365-368.
65. Li D., Law S., Andermann L. Association between degrees of social defeat and themes of delusion in patients with schizophrenia from immigrant and ethnic minority backgrounds. Transcult. Psychiatry 2012, 49(5):735-749.
66. Li F., Nellaker C., Sabunciyan S., Yolken R.H., Jones-Brando L., Johansson A.S., et al. Transcriptional derepression of the ERVWE1 locus following influenza A virus infection. J. Virol. 2014, 88(8):4328-4337.
67. Liu C.H., Keshavan M.S., Tronick E., Seidman L.J. Perinatal risks and childhood premorbid indicators of later psychosis: next steps for early psychosocial interventions. Schizophr. Bull. 2015, 41(4):801-816.
68. Lorenzetti V., Solowij N., Whittle S., Fornito A., Lubman D.I., Pantelis C., et al. Gross morphological brain changes with chronic, heavy cannabis use. Br. J. Psychiatry 2015, 206(1):77-78.
69. Malchow B., Hasan A., Schneider-Axmann T., Jatzko A., Gruber O., Schmitt A., et al. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(Suppl. 2):S155-68.
70. Manrique-Garcia E., Zammit S., Dalman C., Hemmingsson T., Andreasson S., Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol. Med. 2012, 42(6):1321-1328.
71. Markulev C., McGorry P.D., Nelson B., Yuen H.P., Schaefer M., Yung A.R., et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Intervention Psychiatry 2015.
72. McGorry P.D., Nelson B., Phillips L.J., Yuen H.P., Francey S.M., Thampi A., et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J. Clin. Psychiatry 2013, 74(4):349-356.
73. McGrath J.J., Feron F.P., Burne T.H., Mackay-Sim A., Eyles D.W. The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann. Med. 2003, 35(2):86-93.
74. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 2004, 67(2-3):237-245.
75. McGrath J.J., Burne T.H., Feron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr. Bull. 2010, 36(6):1073-1078.
76. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch. Gen. Psychiatry 2010, 67(9):889-894.
77. McGrath J., Brown A., St Clair D. Prevention and schizophrenia-the role of dietary factors. Schizophr. Bull. 2011, 37(2):272-283.
78. McGrath J.J. A Rosetta stone for epidemiology: genomic risk profile scores contain clues related to modifiable risk factors. Epidemiol. Psychiatric Sci. 2015, 24(1):1-5.
79. Meier M.H., Caspi A., Reichenberg A., Keefe R.S., Fisher H.L., Harrington H., et al. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. Am. J. Psychiatry 2014, 171(1):91-101.
80. Monteleone P., Di Filippo C., Fabrazzo M., Milano W., Martiadis V., Corrivetti G., et al. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014, 215(2):263-267.
81. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br. Med. J. 1987, 295(6600):681-682.
82. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
83. Nellaker C., Yao Y., Jones-Brando L., Mallet F., Yolken R.H., Karlsson H. Transactivation of elements in the human endogenous retrovirus W family by viral infection. Retrovirology 2006, 3:44.
84. Nelson B., Yuen H.P., Wood S.J., Lin A., Spiliotacopoulos D., Bruxner A., et al. Long-term follow-up of a group at ultra high risk (prodromal) for psychosis: the PACE 400 study. JAMA psychiatry. 2013, 70(8):793-802.
85. O'Neil A., Itsiopoulos C., Skouteris H., Opie R.S., McPhie S., Hill B., et al. Preventing mental health problems in offspring by targeting dietary intake of pregnant women. BMC Med. 2014, 12:208.
86. O'Neil A., Jacka F.N., Quirk S.E., Cocker F., Taylor C.B., Oldenburg B., et al. A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. BMC Psychiatry 2015, 15:15.
87. Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. Lancet 2016.
88. Pantelis C., Yucel M., Wood S.J., McGorry P.D., Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust. N. Z. J. Psychiatry 2003, 37(4):399-406.
89. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 2005, 31(3):672-696.
90. Pasco J.A., Williams L.J., Jacka F.N., Ng F., Henry M.J., Nicholson G.C., et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br. J. Psychiatry 2008, 193(4):322-326.
91. Patel V., Saxena S. Transforming lives, enhancing communities-innovations in global mental health. N. Engl. J. Med. 2014, 370(6):498-501.
92. Penn D.L., Sanna L.J., Roberts D.L. Social cognition in schizophrenia: an overview. Schizophr. Bull. 2008, 34(3):408-411.
93. Perron H., Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin. Rev. Allergy Immunol. 2010, 39(1):51-61.
94. Perron H., Mekaoui L., Bernard C., Veas F., Stefas I., Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol. Psychiatry 2008, 64(12):1019-1023.
95. Phillips L.J., Velakoulis D., Pantelis C., Wood S., Yuen H.P., Yung A.R., et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr. Res. 2002, 58(2-3):145-158.
96. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust. N. Z. J. Psychiatry 2006, 40(9):725-741.
97. Picken A., Tarrier N. Trauma and comorbid posttraumatic stress disorder in individuals with schizophrenia and substance abuse. Compr. Psychiatry 2011, 52(5):490-497.
98. Pinkham A.E., Penn D.L., Perkins D.O., Graham K.A., Siegel M. Emotion perception and social skill over the course of psychosis: a comparison of individuals at-risk for psychosis and individuals with early and chronic schizophrenia spectrum illness. Cognit. Neuropsychiatry 2007, 12(3):198-212.
99. Rolland A., Jouvin-Marche E., Viret C., Faure M., Perron H., Marche P.N. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J. Immunol. 2006, 176(12):7636-7644.
100. Rossler W., Ajdacic-Gross V., Haker H., Rodgers S., Muller M., Hengartner M.P. Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland. Epidemiol. Psychiatric Sci. 2015, 24(1):69-77.
101. Saha S., Scott J.G., Varghese D., McGrath J.J. The association between general psychological distress and delusional-like experiences: a large population-based study. Schizophr. Res. 2011, 127(1-3):246-251.
102. Sahin S., Yuksel C., Guler J., Karadayi G., Akturan E., Gode E., et al. The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia. Early Intervention Psychiatry 2013, 7(4):414-420.
103. Samele C., Patel M., Boydell J., Leese M., Wessely S., Murray R. Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc. Psychiatry Psychiatr. Epidemiol. 2007, 42(2):117-124.
104. Samplin E., Ikuta T., Malhotra A.K., Szeszko P.R., Derosse P. Sex differences in resilience to childhood maltreatment: effects of trauma history on hippocampal volume, general cognition and subclinical psychosis in healthy adults. J. Psychiatr. Res. 2013, 47(9):1174-1179.
105. Schnell T., Kleiman A., Gouzoulis-Mayfrank E., Daumann J., Becker B. Increased gray matter density in patients with schizophrenia and cannabis use: a voxel-based morphometric study using DARTEL. Schizophr. Res. 2012, 138(2-3):183-187.
106. Schulz J., Sundin J., Leask S., Done D.J. Risk of adult schizophrenia and its relationship to childhood IQ in the 1958 British birth cohort. Schizophr. Bull. 2014, 40(1):143-151.
107. Seidman L.J., Nordentoft M. New targets for prevention of schizophrenia: is it time for interventions in the premorbid phase?. Schizophr. Bull. 2015, 41(4):795-800.
108. Solowij N., Walterfang M., Lubman D.I., Whittle S., Lorenzetti V., Styner M., et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr. Res. 2013, 143(1):179-184.
109. Stowkowy J., Addington J. Maladaptive schemas as a mediator between social defeat and positive symptoms in young people at clinical high risk for psychosis. Early Intervention Psychiatry 2012, 6(1):87-90.
110. Susser E., Patel V. Psychiatric epidemiology and global mental health: joining forces. Int. J. Epidemiol. 2014, 43(2):287-293.
111. Sutkowski N., Conrad B., Thorley-Lawson D.A., Huber B.T. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001, 15(4):579-589.
112. Swift W., Wong A., Li K.M., Arnold J.C., McGregor I.S. Analysis of cannabis seizures in NSW, Australia cannabis potency and cannabinoid profile. PLoS One 2013, 8(7):e70052.
113. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
114. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 2012, 38(3):642-647.
115. Van Lieshout R.J., Voruganti L.P. Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms. J. Psychiatry Neurosci. Jpn. 2008, 33(5):395-404.
116. Van Lieshout R.J., Taylor V.H., Boyle M.H. Pre-pregnancy and pregnancy obesity and neurodevelopmental outcomes in offspring: a systematic review. Obesity Rev. 2011, 12(5):e548-e549.
117. Velakoulis D., Wood S.J., McGorry P.D., Pantelis C. Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Aust. N. Z. J. Psychiatry 2000, 34:S113-S126.
118. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44(7):660-669.
119. Welch K.A., Moorhead T.W., McIntosh A.M., Owens D.G., Johnstone E.C., Lawrie S.M. Tensor-based morphometry of cannabis use on brain structure in individuals at elevated genetic risk of schizophrenia. Psychol. Med. 2013, 43(10):2087-2096.
120. Whitford T.J., Wood S.J., Yung A., Cocchi L., Berger G., Shenton M.E., et al. Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis. Schizophr. Res. 2012, 135(1-3):175-180.
121. Xu M.Q., Sun W.S., Liu B.X., Feng G.Y., Yu L., Yang L., et al. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961Chinese famine. Schizophr. Bull. 2009, 35(3):568-576.
122. Yao Y., Schroder J., Nellaker C., Bottmer C., Bachmann S., Yolken R.H., et al. Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. Genes Brain Behav. 2008, 7(1):103-112.
123. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8(1):131-145.
124. Young J.W., Geyer M.A. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol. 2013, 86(8):1122-1132.
125. Young G.R., Stoye J.P., Kassiotis G. Are human endogenous retroviruses pathogenic? An approach to testing the hypothesis. BioEssays 2013, 35(9):794-803.
126. Young G.R., Mavrommatis B., Kassiotis G. Microarray analysis reveals global modulation of endogenous retroelement transcription by microbes. Retrovirology 2014, 11:59.
127. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008, 65(6):694-701.
128. Zalesky A., Solowij N., Yucel M., Lubman D.I., Takagi M., Harding I.H., et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012, 135(Pt. 7):2245-2255.
129. Zugno A.I., Fraga D.B., De Luca R.D., Ghedim F.V., Deroza P.F., Cipriano A.L., et al. Chronic exposure to cigarette smoke during gestation results in altered cholinesterase enzyme activity and behavioral deficits in adult rat offspring: potential relevance to schizophrenia. J. Psychiatr. Res. 2013, 47(6):740-746.
130. van Dijk D., Koeter M.W., Hijman R., Kahn R.S., van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr. Res. 2012, 137(1-3):50-57.
131. van Nierop M., van Os J., Gunther N., van Zelst C., de Graaf R., Ten Have M., et al. Does social defeat mediate the association between childhood trauma and psychosis? Evidence from the NEMESIS-2 Study. Acta Psychiatr. Scand. 2014, 129(6):467-476.
132. van der Gaag M., Smit F., Bechdolf A., French P., Linszen D.H., Yung A.R., et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 2013, 149(1-3):56-62.